Krebsprädispositionssyndrom-Register 01

Registerleitung:
Prof. Dr. med. Christian Kratz
Prof. Dr. med. Stefan Pfister

Prof. Dr. med. Christian Kratz
Klinik für Pädiatrische Hämatologie und Onkologie der MHH
Telefon: 0511 532-9408
Fax: 0511 532-161026
E-Mail: kratz.christian@mh-hannover.de
Carl-Neuberg-Straße 1, 30625 Hannover

Prof. Dr. med. Stefan Pfister
Hopp-Kindertumorzentrum Heidelberg
Pädiatrische Neuroonkologie, DKFZ
Telefon: 06221 42-4617
Fax: 06221 42-4639
E-Mail: s.pfister@dkfz.de
Im Neuenheimer Feld 580, 69120 Heidelberg

Information for adult patients

ADDRess as a part of

Cancer-Predisposition-Syndrome-Registry-01

Dear Patient,
your physician has informed you that you have been diagnosed with a cancer predisposition syndrome (CPS). One main feature of this genetic condition is an increased cancer risk.

You have already agreed to participate in the cancer predisposition syndrome register 01.

In order to improve medical and psychosocial care, cancer monitoring, diagnosis and treatment for people with DNA repair disorders, patient representatives, physicians from various disciplines and researchers have joined forces to form the "ADDRess" consortium. ADDRess stands for "Abnormal DNA Damage Response" and consists of 10 subprojects. In these subprojects several scientists throughout Germany are working and researching on this research project and pursue the following aims:

- We want to create an infrastructure that facilitates the exchange of information, the coordination of consultations and the input of medical data for both: patients and healthcare professionals. (Subproject 1, Hannover)
- We want to advance psychosocial support in an evidence-based manner. (Subproject 2, Würzburg)
- We want to advance genetic research related to these cancer predisposition syndromes.(Subproject 3, Würzburg)

- We aim to develop new therapeutic strategies for cancer using metabolic profiles of CPS patients. (Subproject 4, Hannover)
- We want to improve early cancer detection through innovative imaging techniques and reduce the need of contrast agents. (Subproject 5, Heidelberg)
- We aim to establish liquid biopsy as a tool for cancer detection and monitoring in DADDR patients. (Subproject 6, Heidelberg)
- We aim to study clonal hematopoiesis, a preleukemic state, in patients with Li-Fraumeni syndrome. (Subproject 7, Hannover)
- We aim to analyze mutational and methylation profiles in DADDR-related cancer. (Subproject 8, 9, Heidelberg)
- We aim to identify therapeutic targets for cancers in DADDRs and develop xenograft mouse models to search for effective therapies that can be tested in early clinical trials. (Subproject 10, Heidelberg)

Brief Overview

Current state of knowledge: Disorders with abnormal DNA damage response (DADDR) are rare genetic diseases with limited DNA repair. The patients share one common feature in shape of an increased cancer risk. The treatment remains complicated due to the genetic disorder. Patients who are treated with analogue radiation or chemotherapy strategies may suffer from an increased level of side effects and intolerances, secondary malignancies and poor treatment outcome, just like cancer-patients without underlying DNA repair defects. Mortality may also be increased. The development of treatment strategies is therefore urgently needed.

Study design: We collect and analyse biospecimen such as blood, bone marrow, tumor specimens, skin and cheek mucosa from individuals with DNA repair defects, in order to improve the medical and psychosocial care, as well as surveillance strategies, diagnosis and treatment of patients with underlying DNA repair disorders.

Procedures and processes: At the time that blood draws are normally completed for your medical care, blood samples will be taken and stored for research purposes. An additional blood sample may be necessary in individual cases. If possible, about 45ml of blood should be taken. Bone marrow will only be collected as part of a diagnostic or routine bone marrow puncture. Skin biopsies will be performed as part of a bone marrow collection if possible. In some exceptional cases it is possible that an additional skin sample collection may be necessary if an adequate skin sample could not be collected during the diagnostic bone marrow puncture. A tumor specimen is collected for research purposes only when a biopsy or tumor resection is performed as part of the patient's medical care. The size of the collected tumor specimen cannot be predicted as it depends on the size of the removed tumor sample. It is assured that research samples will be collected only if there is sufficient tumor material for diagnostic and therapeutic decisions for the patient. Therefore, the collection of tumor specimen for our registry does not impose additional risks. The cheek swab is additionally performed with a cotton swab to obtain DNA. The findings will be transferred to the CPS register and the other subprojects. Since this is a long-term investigation that addresses the course of a condition over several years, the study has no defined duration.

The Risks and Benefits of Participation

Expected individual benefit:
Donating your biospecimen and medical data will not necessarily lead to a direct benefit to you. Our analysis serves primarily as scientific research and is not intended as actionable conclusions for your health. Nevertheless, the research may lead to findings that may be of importance to your health. In the situation, when an analysis reveals evidence of a severe previously unknown condition, that can potentially be treated or prevented, we may want to contact you in order to give you this information (see below).

In case you do not wish to receive this type of feedback, please check the box containing "no" on the informed consent. Any time, you can change your decision for or against this feedback option by letting us know. However, please note that you may be obligated to disclose health related information that you receive through our registry, if you prefer this option, to other parties such as health- or life insurance companies. This may be a disadvantage for you.

The statement above is also relevant to genetic analyses and the discovery of genetic conditions. Therefore, this information may be relevant for family members and family planning.

In the long-term, biospecimen and data collected through our registry is meant eventually to improve the care of patients with cancer predisposition syndromes, which contains DNA repair defects (possibly including participants of the registry). For example, we would like to explore the role of regular evidence-based surveillance strategies.

General Benefit of the Registry:
Medical studies of this kind aim at a better understanding of the processes associated with disease development and improvement in diagnosis and care. Other patients with a cancer predisposition syndrome not participating in this research may benefit from our findings because our research aims at improving the care of all affected patients. Through the collection of biospecimen from individuals with a cancer predisposition syndrome, cancer research in general is advanced. There may be benefit for patients with cancer even in the absence of a cancer predisposition syndrome. We know that mechanism playing a role in individuals with a cancer predisposition syndrome may be relevant for cancer patients on the whole. In theory, it is possible that our research contributes to better therapy and prognosis of cancer patients.

Risks and Disadvantages of participation:
We would like to collect blood samples, bone marrow, tumor specimen, skin biopsies as well as cheek swabs. Apart from the complications that may arise with a blood or bone marrow collection or skin biopsy, there are no other physical risks for you.

Every ascertainment, storage, transfer of data is associated with the risk of breaching the confidentiality of the data (e.g. risk of identifying your person/information), which may be especially relevant for genetic information. It is impossible to entirely exclude this type of risk. This risk increases with the amount of connected data, especially if you are publishing genetic information in the internet on your own. Please see below regarding data and material security.

Purpose of collecting biospecimen:
The biomaterials are either sent to the registry in Hannover or directly to one of the 10 ADDRess subgroups. The respective recipient is determined depending on the sample. For example, fresh tumor samples for subproject 10 are sent directly to Heidelberg. The skin samples will be sent directly to Würzburg for subproject 3. The further samples are collected in the registry in Hannover, coordinated and sent to the corresponding subgroups.

Protection of your biospecimen and data:
The biomaterials are either directly sent to the corresponding subgroups or coordinated by the CPS-registry in Hannover. Further Biospecimen will be stored in the biobank of Hannover Medical School of indefinite duration. Clinical data will be stored on a server of Medical School Hannover. The initials of the first name and surname, the quarter and year of birth, and the sex are recorded. Full names or dates of birth are not stored. However, through the link to the CPS register, it may be possible for the register team to identify you. However, personal data can only be viewed by the collecting physician, the registry team and the staff of the individual subprojects. Your personal data will not be disclosed to third parties apart from ADDRess subprojects, the therapy study of the respective cancer and the Children's Cancer Registry. All identifying information (name, date of birth, address, etc.) will be replaced by an identification code (pseudonymized). Only after this process, biospecimen and data will be made available for research. Transfer of identifying information to researchers beyond the ADDRess subprojects or others such as insurances und employers does not occur.

The encoded biomaterials and medical data can be transferred to universities, research institutes and researching companies, possibly also abroad, for more precisely defined medical research purposes according to previously defined criteria. It is possible that our registry data will be connected to your data in other databases, in accordance with the law. When data is transferred abroad, it may not be possible to maintain the same high level of data protection as in Germany. Biomaterials and data issued to researchers may only be used for the predetermined research purpose and may not be passed on by the recipient for other purposes. Remaining material will be returned to the Hannover Unified Biobank or destroyed.
The prerequisite for the use of biomaterials and data for a concrete medical research project is, in principle, that the research project has been evaluated and approved by an ethics committee.
Publications are written in an anonymized fashion to prohibit identification of individual participants. This implies the situation, if data is entered into scientific online databases. A publication of your entire genetic information (genome) is impossible without your explicit written permission.

Financial benefits to you or the biobank:
You will not be paid for allowing us to collect and store your biospecimen and data. You will not receive financial or other compensation, should findings resulting from the research on your biospecimen become commercially valuable. With the transfer of the biomaterials to the ADDRess project within the CPS Registry, they become the property of the CPS-R01 Registry of the German Society of Pediatric Oncology and Hematology. You authorize the registry to use your data for research purposes. Your specimen and data will not be sold. However, the biobank can ask researchers for an expense allowance for providing specimen to collaborating researchers.

Other Questions and Concerns

Is it possible that you will be contacted regarding the registry?
On a regular basis, results from your medical visits are being forwarded to the registry team. In case of missing data, it could be useful that you are contacted at a later time point in order to request additional information or specimen. Also, this contact could occur to request your permission for connecting your data with other databases or in order to give feedback to you or your physician on findings that may be relevant to your health. You will not be contacted through the registry team directly but through your physician or the health care institution that cares for you.

In case you do not wish to be contacted, please check the box containing “no” on the informed consent.

What is your right of withdrawal from the registry?
Any time and without justification and disadvantages you may withdraw your consent that allows us to use your biospecimen and data. In case you withdraw your consent, you may decide whether your specimen should be destroyed or be anonymized. In the latter situation, we delete the identification code that allows us to connect a specimen to you. One has to keep in mind that such an anonymization process cannot entirely exclude the small chance that a specimen can be tracked back to you. Deletion of data may be limited technically feasibility, however. You can also decide whether your already collected data should be deleted or may be further used in anonymized form. Data can only be deleted under the conditions of Art. 17 DSGVO. As soon as the purchase of the biomaterials and other data relating to your person has been deleted (anonymization), destruction is no longer possible. In addition, data from analyses already carried out can no longer be removed.

In case you would like to withdraw your consent, please contact:

Christian P. Kratz, MD, Director
Pediatric Hematology and Oncology
Hannover Medical School
Carl-Neuberg-Str. 1
30625 Hannover
Germany
Phone: +49 (0)511 532 6711
Fax: +49 (0)511 532 9120
Email: kratz.christian@mh-hannover.de

Is your participation voluntary?
Your participation in this registry is voluntary. In case you prefer not to participate, you will experience no disadvantage.

Where can I get additional information?

Should you have additional questions, please contact your physician prior to giving your consent. You can also contact Prof. Kratz or Prof. Pfister. Information regarding findings can be found on www.krebs-praedisposition.de.

We are happy to address your questions.
Sincerely

Christian Kratz, MD Stefan Pfister, MD

Krebsprädispositionssyndrom-Register 01

Registerleitung:
Prof. Dr. med. Christian Kratz
Prof. Dr. med. Stefan Pfister

Prof. Dr. med. Christian Kratz
Klinik für Pädiatrische Hämatologie und Onkologie der MHH
Telefon: 0511 532-9408
Fax: 0511 532-161026
E-Mail: kratz.christian@mh-hannover.de
Carl-Neuberg-Straße 1, 30625 Hannover

Prof. Dr. med. Stefan Pfister
Hopp-Kindertumorzentrum Heidelberg
Pädiatrische Neuroonkologie, DKFZ
Telefon: 06221 42-4617
Fax: 06221 42-4639
E-Mail: s.pfister@dkfz.de
Im Neuenheimer Feld 580, 69120 Heidelberg

Informed consent for adult patients

ADDRess project

As a part of Cancer-Predisposition–Syndrome-R01

Patient (Last Name, First Name) _____ Date of Birth (dd/mm/yy) _____

Treating Hospital _____

I have read the information sheet and had the opportunity to ask questions. My questions were answered comprehensively and comprehensibly. I know that my participation is voluntary and that I can retract my consent any time without justification and without disadvantages. I had enough time to consider my decision to participate and make my own decision.

I give my informed consent that my biospecimen as well as medical information as described in the information sheet are sent to the CPS-R01 to be used for medical research purposes especially for the ADDRess project.

I transfer ownership of the biospecimen to Medical School Hannover.

I approve that I may be contacted at a later time point for the following reasons, please check the boxes with "yes" or "no":

- For the collection of additional medical information/biospecimen □ yes □ no
- If further consent is necessary for the use of your medical information □ yes □ no
- If our research identifies actionable findings that may be relevant to your health □ yes □ no

This contact will occur through the institution that collected my biospecimen and data **or** by the following physician (please give this information to the physician if the latter is preferred):

Physician name and address: _____

Data Protection Statement

I approve that the registry team conducts the following actions (also described in the information sheet):

- Collects and stores the initials of my first and last name as well as the quarter and year of birth,

- Collects and stores identifying materials and information related to my health

- After the collection, the biospecimen and data will be coded to pseudonymized to be used for the ADDRess project

- Coded non-identifying information will be used for scientific publications and online databases

My biospecimen and data may be used for medical research purposes for an unlimited time period.

In a non-identifiable manner, biospecimen and data may be transferred to universities, research institutes/companies for the purpose of medical research. This may include international research projects.

Identifying data can be exchanged with the ADDRess subprojects, the therapy study of the corresponding cancer and the children's cancer registry.

I was informed that I may withdraw my consent to participate in the registry/ ADDRess project any time without justification. In case of withdrawal, I may request that any remaining biospecimen and data be destroyed, deleted or anonymized.

Please note: If an analysis has been completed, the data cannot be removed.

I have the right to be informed about the stored personal data concerning myself (Art. 15 DS-GVO). If I discover that incorrect personal data of me is being processed, I can demand correction (Art. 16 DS-GVO).

I have the right to demand the deletion of personal data if certain reasons for deletion exist. This is the case, for example, if the personal data are no longer necessary for the purpose for which they were originally collected or processed, or if I revoke my consent and there is no other legal basis for the processing (Art. 17

DS-GVO). Furthermore, I have the right to limit the processing of my personal data (Art. 18 DS-GVO), to data transferability (Art. 20 DS-GVO) and a general right of objection (Art. 21 DS-GVO).

Data controller: Christian Kratz, MD
Pediatric Hematology and Oncology, OE 6780
Carl-Neuberg-Straße 1
30625 Hannover
Germany

If I have any questions or if I have the opinion that the processing of my personal data is not lawful, I have the option of contacting the MHH data protection officer:

Datenschutzbeauftragte der MHH
OE 0007
Carl-Neuberg-Straße 1
30625 Hannover
Germany

I have the right to complain at the supervisory authority if I believe that the processing of my personal data is not lawful.
The address of the supervisory authority responsible for the MHH is:

Die Landesbeauftragte für den Datenschutz Niedersachsen
Prinzenstraße 5
30159 Hannover
Germany

I am aware that the data protection regulations set out in the information letter also applies.

I have received a copy of the information sheet and the signed informed consent. The original is kept in the patient's medical record.

In addition, I was orally informed about the ADDRess project.

CONFIRMATION OF THE PATIENT

_____

Patient name (in block capitals)

_____ _____

Place, date Signature patient

CONFIRMATION FROM THE ATTENDING PHYSICIAN

I have discussed the ADDRess project and the accompanying research including the patient information and the declaration of consent with the patient. All questions were answered comprehensively. I have explained to the patient that participation is voluntary.

_____

Name of physician (in block capitals)

_____ _____

Place, date Signature of attending physician